Prognostic factors in patients with small cell lung carcinoma

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 237-241

  Arinc, S ^a   Gonlugur, U ^b   Devran, O ^a   Erdal, N ^a   Ece, F ^a   Ertugrul, M ^a   Derince, D ^a   Oruc, O ^a   Hazar, A ^a  

^a Chest Surgery Training and Research Hospital   (Turkey)

^b CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Carcinoma: small cell; Prognosis; Superior vena cava syndrome

Indexed keywords

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; COMORBIDITY; DEMOGRAPHY; DISEASE DURATION; FEMALE; HUMAN; HYPOALBUMINEMIA; KARNOFSKY PERFORMANCE STATUS; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SMOKING; SUPERIOR CAVA VEIN SYNDROME; SURVIVAL TIME; WEIGHT CHANGE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 77956899410     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9198-8     Document Type: Article

References (15)

1. Gonlugur TE, Gonlugur U. Comorbidity as a prognostic factor in small cell lung cancer. Tumori. 2006;92:423-428.
2. Tas F, et al. Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer. Acta Oncol. 1999;38:1011-1015.
3. The World Health Organization. The World Health Organization histological typing of lung tumors. Second edition. Am J Clin Pathol. 1982; 77:123-136.
4. Bulbul Y, Oztuna F, Topba M, Ozlu T. Survival analyses of patients with thoracic complications secondary to bronchial carcinoma at the time of diagnosis. Respiration. 2005;72:388-394.
5. Würschmidt F, Bünemann H, Heilmann HP. Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. Int J Radiat Oncol Biol Phys. 1995;33:77-82.
6. Tai P, et al. Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment. BMC Cancer. 2007;7
7. Christodolou C, et al. Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study. Anticancer Res. 2002;22:3749-3757.
8. Bremnes RM, et al. The value of prognostic factors in small cell lung cancer: Results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer. 2003;39:303-313.
9. Sagman U, et al. Small-cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol. 1991;9:1639-1649.
10. Paesmans M, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 2000;89:523-533.
11. Watine J. Prognostic factors for patients with small cell lung carcinoma. Cancer. 2002;94:576-578.
12. Quoix E, et al. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer. 2000;30:127-34.
13. Stokkel MP, van Eck-Smit BL, Zwinderman AH, Willems LN, Pauwels EK. Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma. J Cancer Res Clin Oncol. 1998;124:215-219.
14. Kristjansen PE, Osterlind K, Hansen M. Detection of bone marrow relapse in patients with small cell carcinoma of the lung. Cancer. 1986;58:2538-2541.
15. Cooper S, Spiro S. Small cell lung cancer: treatment review. Respirology. 2006;11:241-248.